In conclusion, our data demonstrate that the antidiabetic drug METF synergistically eradicating NSCLC cells in combination with the CSC killer SAL could be a promising treatment option for NSCLC patients irrespective of their EGFR, KRAS, EML4/ALK and LKB1 status. The gene discussed is STK11; the disease is non-small cell lung carcinoma.